Protocol No. MSDC-0602K-C009NASH: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients with NASH (EMMINENCE™)

Project: Research project

Project Details

StatusActive
Effective start/end date12/18/1712/18/20

Funding

  • Chiltern International, Inc. (MSDC-0602K-C009NASH)
  • Cirius Therapeutics, Inc. (MSDC-0602K-C009NASH)